Cleo Sets Up US Lab Ahead Of Ovarian Cancer Test Validation
COV: $0.290 +1.75% · MC: $38M
Cleo Diagnostics has established the US laboratory infrastructure for clinical validation of its pre-surgical ovarian cancer test, with reproducibility studies underway and testing anticipated to begin within the next month. The program is expected to assess approximately 1,470 samples across three study groups and support a planned FDA 510(k) submission in the first half of 2027.

Comments